Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention

Abstract
Cancer treatments are often more successful when the disease is detected early. We evaluated the feasibility and safety of multicancer blood testing coupled with positron emission tomography–computed tomography (PET-CT) imaging to detect cancer in a prospective, interventional study of 10,006 women not previously known to have cancer. Positive blood tests were independently confirmed by a diagnostic PET-CT, which also localized the cancer. Twenty-six cancers were detected by blood testing. Of these, 15 underwent PET-CT imaging and nine (60%) were surgically excised. Twenty-four additional cancers were detected by standard-of-care screening and 46 by neither approach. One percent of participants underwent PET-CT imaging based on false-positive blood tests, and 0.22% underwent a futile invasive diagnostic procedure. These data demonstrate that multicancer blood testing combined with PET-CT can be safely incorporated into routine clinical care, in some cases leading to surgery with intent to cure.
Funding Information
  • National Institutes of Health (#CA6973)
  • National Institutes of Health (#U01 CA152753)
  • National Institutes of Health (#U01 CA230691)
  • National Institutes of Health (#P50 CA62924)
  • National Institutes of Health (R44CA203350)
  • National Institutes of Health (R37CA230400)
  • National Institutes of Health (T32-GM007309)
  • National Institutes of Health (HHSN261201600034C)
  • Burroughs Wellcome Fund
  • John Templeton Foundation
  • John Templeton Foundation
  • Lustgarten Foundation
  • Virginia and D.K. Ludwig Fund for Cancer Research
  • Billi and Bernie Marcus Foundation
  • The Sol Goldman Center for Pancreatic Cancer Research
  • Susan Wojcicki and Dennis Troper (N/A)
  • The Conrad R. Hilton Foundation
  • The Rolfe Foundation